CUE BIOPHARMA INC. - COMMON STOCK

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

29 ноя 2024 16:30:00 Источник Nasdaq GlobeNewswire

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference

25 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire

Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights

14 ноя 2024 16:05:00 Источник Nasdaq GlobeNewswire

Cue Biopharma Announces Strategic Organizational Transition

14 ноя 2024 08:00:09 Источник Nasdaq GlobeNewswire

Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

12 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire

Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting

08 ноя 2024 13:30:00 Источник Nasdaq GlobeNewswire

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

04 окт 2024 09:00:00 Источник Nasdaq GlobeNewswire

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

26 сен 2024 23:26:30 Источник Nasdaq GlobeNewswire

Cue Biopharma Announces Proposed Public Offering

26 сен 2024 23:10:15 Источник Nasdaq GlobeNewswire

Cue Biopharma Announces Proposed Public Offering

26 сен 2024 16:27:02 Источник Nasdaq GlobeNewswire

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

09 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference

03 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

19 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire

Cue Biopharma to Host Business Update Call and Webcast

13 авг 2024 08:00:01 Источник Nasdaq GlobeNewswire

Cue Biopharma Announces Strategic Prioritization of Autoimmune Programs Enabling Optimization of Workforce and Reduction of Capital Requirements

25 июл 2024 16:05:00 Источник Nasdaq GlobeNewswire

Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting

04 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024

03 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire

Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

09 май 2024 16:05:01 Источник Nasdaq GlobeNewswire

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

08 май 2024 08:00:00 Источник Nasdaq GlobeNewswire

Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference

07 май 2024 08:00:00 Источник Nasdaq GlobeNewswire